NEO
Diagnostics & Research · Healthcare
COO
2021-07-05–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Neogenomics Inc publishes a filing, an earnings call transcript or a press release.
Get NEO alertsGeorge A. Cardoza is recorded as COO at Neogenomics Inc (NEO) since July 5, 2021. Neogenomics Inc reported in an 8-K filed March 9, 2022 that George A. Cardoza retired as President and Chief Operating Officer, Laboratory Operations, effective March 31, 2022. Neogenomics Inc reported in an 8-K filed July 7, 2021 that George A. Cardoza was appointed President and Chief Operating Officer, Lab Operations, effective July 5, 2021. The proxy statement of Neogenomics Inc reports total compensation of $1,107,374 for George A. Cardoza in fiscal 2019, including a base salary of $380,000. Disclosed compensation is on record for 3 fiscal years. George A. Cardoza has spoken on 7 earnings calls across 1 company, most recently for Neogenomics Inc on February 23, 2022. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Chris Smith (CEO and Board Member), Christopher Smith (CEO and Board Member), Lynn A. Tetrault (CEO, Chairman and Board Member) and 7 others.
“On March 9, 2022, George A. Cardoza, NeoGenomics, Inc.’s \(the “Company”\) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.”
“George A. Cardoza, age 59, has been appointed President and Chief Operating Officer, Lab Operations effective July 5, 2021.”
“Yes, certainly as Mark mentioned, one of our goals on the international side, we’re thrilled that China is open now, but with operations in the United States, with operations in Switzerland, Singapore, and China, we really believe that the footprint is built, and certainly we have capacity at those international labs…”
“We’ve already increased investment in Pharma Services. We’ve added sites internationally, and while COVID-19 has hampered access, our teams have kept the momentum going.”
“Yes, the beauty of an assay like RaDaR is it's completely suitable for both residual disease detection following surgery and ongoing monitoring for recurrent disease.”
“I mean, I hope you see in the 43% year-on-year growth, that obviously it is starting to convert certainly. So, and I think if you look at the back half of the year, you see 30% growth.”
“I am excited to have the opportunity today to discuss our Pharma Services business. The strategic investments we have made in recent years, together with additional planned investments, have helped us create a differentiated platform for continued growth.”
2021-07-05–present
2021-07-05–2022-03-31
Proxy statement
Start not stated–2020-04-15
Last confirmed by a filing; no departure on record
Start not stated–2022-03-31
NEO
Diagnostics & Research · Healthcare
COO
2021-07-05–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Neogenomics Inc (NEO) | President of Pharma Services | $380,000 | $1,107,374 |
| 2018 | Neogenomics Inc (NEO) | President of Pharma Services | $370,000 | $1,056,522 |
| 2017 | Neogenomics Inc (NEO) | President of Pharma Services | $352,692 | $1,107,109 |